• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?

    Simply Wall St·08/16/2026 05:19:50
    Listen to the news
    • Mirum Pharmaceuticals, Inc. reported past earnings for the second quarter and first half of 2026, disclosing a net loss of US$67.23 million for the quarter and a very large six‑month net loss, with basic loss per share from continuing operations rising to US$1.06 for the quarter and US$14.03 for the half year.
    • The sharp widening of losses compared with the prior year highlights how Mirum’s cost base and investment intensity have increased relative to its current revenue scale.
    • We’ll now examine how Mirum’s sharply higher recent net losses interact with its prior growth-focused investment narrative and analyst expectations.

    Outshine the giants: these 17 early-stage AI stocks could fund your retirement.

    Mirum Pharmaceuticals Investment Narrative Recap

    To own Mirum today, you need to believe its rare disease portfolio can eventually justify heavy investment and deep current losses. The sharp swing to a six month net loss of US$857.38 million intensifies the near term focus on cash burn and funding, even as clinical and regulatory catalysts remain central. For now, the headline loss does not appear to change the most important upcoming drug approval and data milestones, but it likely heightens attention on financing risk.

    Among recent announcements, the FDA’s Priority Review for zilurgisertib in fibrodysplasia ossificans progressiva, with a September 26, 2026 PDUFA date, stands out. This potential approval sits alongside VISTAS and AZURE-1 readouts as a key catalyst that could broaden Mirum’s revenue base beyond Livmarli, which matters even more when losses widen. Whether these programs can offset rising R&D and SG&A will be central to how investors interpret the latest results.

    But against this backdrop of promising late stage assets, the combination of a six month net loss of US$857.38 million and prior shareholder dilution is something investors should be aware of...

    Read the full narrative on Mirum Pharmaceuticals (it's free!)

    Mirum Pharmaceuticals' narrative projects $1.1 billion revenue and $234.1 million earnings by 2029.

    Uncover how Mirum Pharmaceuticals' forecasts yield a $144.15 fair value, a 43% upside to its current price.

    Exploring Other Perspectives

    MIRM 1-Year Stock Price Chart
    MIRM 1-Year Stock Price Chart

    Some of the most optimistic analysts were expecting Mirum to reach about US$1.3 billion in revenue and US$436 million in earnings by 2029, yet the latest US$857 million half year loss shows how different your view might be if you worry that heavy R&D spending and trial risks could still derail that path.

    Explore 3 other fair value estimates on Mirum Pharmaceuticals - why the stock might be worth over 4x more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready For A Different Approach?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.